financetom
Business
financetom
/
Business
/
Ex-Goldman Sachs banker wins part of appeal, still faces extradition to US
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Ex-Goldman Sachs banker wins part of appeal, still faces extradition to US
Jun 7, 2024 2:54 AM

LONDON, June 7 (Reuters) - Former Goldman Sachs

banker Asante Berko who is wanted in the United States for

allegedly paying bribes to Ghanaian officials on Friday won part

of his appeal, but still faces extradition to the United States.

Berko was charged with six offences in New York in 2020

relating to his time working for Goldman Sachs ( GS ).

He appealed against the decision to extradite him at

London's High Court last month after a judge sent his case to

British ministers in 2023.

Berko's lawyers said he could not be extradited in relation

to three of the charges, which allege that he wilfully failed to

file reports of foreign bank accounts in the U.S., as the

allegation was not a criminal offence in Britain.

They also argued that Berko's alleged offending took place

in Britain or in Ghana, meaning he should not stand trial in the

United States.

Judge Charles Bourne ruled on Friday that Berko should not

be extradited to face the three charges of failing to file

reports of foreign bank accounts.

The judge said Berko would otherwise be at risk of "being

convicted and imprisoned for conduct which would not amount to

an offence in this country".

However, Bourne rejected the rest of Berko's appeal, meaning

he still faces extradition.

"Although the appellant was based in the UK at the time of

the relevant conduct, the conspiracy was entirely international

in nature," Bourne ruled.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Oncternal Therapeutics Ends Clinical Studies, Explores Strategic Options; Shares Fall
Oncternal Therapeutics Ends Clinical Studies, Explores Strategic Options; Shares Fall
Sep 13, 2024
11:13 AM EDT, 09/12/2024 (MT Newswires) -- Oncternal Therapeutics' ( ONCT ) shares sank 58% in recent Thursday trading after the company said it has decided to discontinue its clinical studies and explore strategic alternatives. The company also said it will discontinue all product development activities, lay off some staff, and implement other cost-cutting measures while exploring alternatives, which may...
Buckle Insider Sold Shares Worth $854,496, According to a Recent SEC Filing
Buckle Insider Sold Shares Worth $854,496, According to a Recent SEC Filing
Sep 13, 2024
11:08 AM EDT, 09/12/2024 (MT Newswires) -- Dennis H Nelson, Director, President & CEO, on September 10, 2024, sold 20,453 shares in Buckle (BKE) for $854,496. Following the Form 4 filing with the SEC, Nelson has control over a total of 2,310,552 shares of the company, with 324,000 shares held directly and 1,986,552 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/885245/000088524524000087/xslF345X05/wk-form4_1726153070.xml Price: 41.56,...
--Street Color: US FDA Authorizes Over-the-Counter Hearing Aid Software for Apple's AirPods Pro
--Street Color: US FDA Authorizes Over-the-Counter Hearing Aid Software for Apple's AirPods Pro
Sep 13, 2024
11:09 AM EDT, 09/12/2024 (MT Newswires) -- Price: 222.76, Change: +0.10, Percent Change: +0.04 ...
Update: Moderna Shares Fall After Cutting Annual R&D Spending by $1.1 Billion From 2027
Update: Moderna Shares Fall After Cutting Annual R&D Spending by $1.1 Billion From 2027
Sep 13, 2024
11:09 AM EDT, 09/12/2024 (MT Newswires) -- (Updates with the latest stock movement in the headline and the first paragraph.) Moderna ( MRNA ) shares fell more than 18% in recent Thursday trading after the company said it is reducing its annual R&D expense by about $1.1 billion starting in 2027 in light of recent commercial challenges. The company now...
Copyright 2023-2026 - www.financetom.com All Rights Reserved